Experimental Dual-Targeting T-Cell therapy takes on tough lymphomas
NCT ID NCT07168291
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial will test a new type of immune cell therapy called bispecific AbTCR T-cells in 3 adults with relapsed or refractory B-cell lymphoma (including diffuse large B-cell, follicular, and Burkitt lymphoma). The cells are designed to target two proteins (CD19 and CD22) on cancer cells. The main goal is to check safety and side effects, with a secondary look at how well the tumors respond. Participants will receive chemotherapy before the cell infusion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bispecific AbTCR (anti-CD19/CD22)-T cells
- What this could lead to
- If it works, this could point toward a new treatment option for patients with hard-to-treat B-cell lymphomas that have not responded to standard therapies.
- What could go wrong
- This is a very early, tiny trial (only 3 participants) focused on safety. The treatment may cause serious side effects, and it is too soon to know if it will be effective or widely available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BURKITT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a single shot build a cancer army inside the body?
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Can a Three-Drug cocktail replace chemo for follicular lymphoma?